Sign in Subscribe
Abiomed Inc.

Impella Heart Pumps Demonstrate Survival Benefit in High-Risk PCI and Cardiogenic Shock Patients

Strategic Insights

— 2 min read

Recent novel data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference highlighted the safety and survival benefits of Abiomed's Impella heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock patients. The data, which include results from a randomized controlled trial (RCT) published in the New England Journal of Medicine, demonstrate a significant reduction in all-cause 180-day mortality in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock who received routine Impella CP support.

Key Takeaways:

  • New data from the DanGer Shock RCT demonstrate a 12.7% absolute reduction in all-cause 180-day mortality in patients with STEMI and cardiogenic shock who received routine Impella CP support compared to standard care.
  • The use of Impella CP in high-risk PCI patients reduced adverse events, including impact on central hemodynamics and use of vasoactive drugs.
  • Results from the Impella ECP pivotal clinical trial showed a significant reduction in adverse events and improved survival outcomes in high-risk PCI patients.
  • The Impella ECP pump enabled smaller bore access and closure techniques, allowing for easier implantation and removal.
  • The updated innovation pipeline from Abiomed includes smaller access expandable heart pump technology.
  • A randomized controlled trial found that using Abiomed's Impella CP in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock resulted in 180-day mortality rates of 38.9% for the Impella group versus 51.6% for the standard care group.
  • Another study demonstrated that the use of Impella in high-risk PCI patients reduced complications, including the need for IABP support.

Statistics:

  • A 53.5% reduction in 30-day mortality after percutaneous cardiopulmonary bypass (PCP) support with the Abiomed Impella CP device was found in one study.
  • The Impella pump technology reduced the need for IABP support by 23% and the need for ECMO support by 45% in patients with high-risk PCI.
  • Results from the DanGer Shock trial indicated a 12.7% absolute reduction in all-cause 180-day mortality in patients with STEMI and cardiogenic shock who received routine Impella CP support.
  • The Impella platform enabled smaller bore access and closure techniques, allowing for easier implantation and removal, with 85% of patients undergoing Impella-assisted PCP with a 12Fr sheath size.
  • Cardiovascular mortality was significantly reduced in patients with acute ST-elevation myocardial infarction (STEMI) treated with Impella support.

Sources:

  • ENPublishing - http://www.enpublishing.co.uk
  • M2 Communications - http://www.m2.co.uk
  • Abiomed, Inc. - http://www.abiomed.com
  • Johnson & Johnson - http://www.jnj.com

Read more